An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

Multicenter Open-label Randomized, Comparative Clinical Study to Evaluate Efficacy and Safety of Algeron (Cepeginterferon Alfa-2b, CJSC "BIOCAD", Russia) With Ribavirin Compared to PegIntron (Peginterferon Alfa-2b, Schering-Plough Labo N.V., Belgium) With Ribavirin in Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients

The purpose of the study is to demonstrate the noninferiority of Algeron in combination with ribavirin compared to PegIntron in combination with ribavirin in treatment of chronic hepatitis C in Human Immunodeficiency Virus-1 infected patients

Study Overview

• Status: Completed
• Conditions: Hepatitis; Hepatitis C; Hepatitis C/ Human Immunodeficiency Virus Coinfection
• Intervention / Treatment: Drug: Algeron; Drug: PegIntron

Detailed Description

The course of treatment in both groups shall be 12 weeks, and efficacy analysis, i.e. rate of rapid (after the 4th week) and early (after the 12th week) virologic response will be based on polymerase chain reaction data. For patients with treatment failure after the 12th week the antiviral therapy shall be discontinued. All patients who require further anti-viral treatment will receive a combination treatment with Algeron / PegIntron and ribavirin for another 36 weeks. Sustained virologic response will be assessed 24 weeks after last dose of study treatment.

• Study Type: Interventional
• Enrollment (Actual): 140
• Phase: Phase 3

Contacts and Locations

Study Locations

• Russian Federation
  • Nizhny Novgorod, Russian Federation, 603005
    • State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases"
  • Sankt-Petersburg, Russian Federation, 190103
    • State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department
  • Saratov, Russian Federation, 410012
    • State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine
  • Vladivostok, Russian Federation, 690002
    • State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation
  • Volgograd, Russian Federation, 400040
    • State Healthcare Institution "Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases"
  • Republic Of Tatarstan
    • Kazan, Republic Of Tatarstan, Russian Federation, 420097
      • State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Signed Informed Consent Form.
• Chronic hepatitis C (genotypes 1а, 1b, 2, 3, 4) confirmed by positive result of hepatitis C virus ribonucleic acid during > 6 months before screening visit or accompanied with increase in alanine aminotransferase (ALT) level > 6 months before screening visit.
• Confirmed Human Immunodeficiency Virus-1 infection based on enzyme-linked immunosorbent assay and immune blotting results.
• Clinically sustained phase of Human Immunodeficiency Virus-1 infection with absence of active opportunistic Human Immunodeficiency Virus-associated diseases for at least 30 calendar days before inclusion in the study.
• Level of CD4+-lymphocytes is not less than 500 cells/mm3 for patients not requiring highly active antiretroviral therapy and which will not be assigned to antiretroviral therapy during the study period.
• For patients receiving sustained highly active antiretroviral therapy for not less than 12 weeks and planning to continue comply with this treatment regimen during the following 24 weeks, level of CD4+-lymphocytes ≥300 cells/mm3, Human Immunodeficiency Virus ribonucleic acid ≤50 copies/ml.
• Men and women aged 18 to 70 inclusively.
• Body mass index in the range of 18 - 30 kg/m2 inclusively .
• Preserved protein-synthetizing liver function (International Normalized Ratio < 1.7, albumin > 35 g/l).
• Absence of signs of hepatic encephalopathy and ascites according to clinical examination and ultrasound examination.
• Patients with preserved child-bearing potential and their partners agree to use barrier method of contraception during the whole period of therapy and during 7 months after the treatment completion.
• Documentary confirmed results of liver elastography (fibroscan) during last year before enrollment in the study or patient agreement to undergo this examination during screening.

Exclusion Criteria:

• Intolerance of alfa-interferons, ribavirin or any components of tested drug product based on medical history.
• Presence of hepatitis B, A, E markers.
• Presence of documentary confirmed clinically significant concurrent liver diseases (alcoholic liver cirrhosis, drug-induced liver cirrhosis, autoimmune hepatitis, hemochromatosis, Wilson's disease, non-alcoholic steatohepatitis, biliary cirrhosis etc.).
• Past history of Hepatitis C Virus treatment with interferon alfa or pegylated interferon alfa.
• For patients receiving sustained highly active antiretroviral therapy - presence of nevirapine, stavudine, zidovudine, didanosine in treatment regimen.
• Use of injectable and non-injectable interferons alfa/ interferon inducers for any indication (except for hepatitis C), radiotherapy, cytotoxic chemotherapy for one month prior to inclusion in the study.
• Cholestic hepatitis (level of direct bilirubin, alkaline phosphatase, gamma glutamyltransferase, exceeding upper normal limit in > 5 times).
• Decompensated liver cirrhosis confirmed with results of laboratory analyses (Child-Pugh class B, C) or ultrasound examination.
• Any documentary confirmed autoimmune diseases (such as Crohn's disease, ulcerative colitis, systemic lupus erythematosus, idiopathic thrombocytopenic purpura, scleroderma, autoimmune hemolytic anemia, severe psoriasis).
• Deviations of hematologic (hemoglobin less than lower normal limit; neutrophils < 1.5 x 10^9/l; thrombocytes < 90 x 10^9/ l) and biochemical (creatinine level > 1.5 times higher upper normal limit, ALT is > 10 times higher upper normal limit) parameters.
• Documentary confirmed diagnosis of hemoglobinopathy (for example, thalassemia, sickle-cell anemia).
• Severe depression, schizophrenia, any other mental disorders which according to the investigator are contraindications for antiviral treatment.
• Epilepsy and/or central nervous system disorder.
• Disorder of thyroid function (level of thyroid stimulating hormone out of the normal range).
• Documentary confirmed or suspected hepatocellular carcinoma based on the results of alfa-fetoprotein (AFP) assay ≥ upper normal limit.
• Antinuclear antibodies (ANA) titer measured at screening is not less than 1:640 or documentary confirmed signs of autoimmune hepatitis based on the results of biopsy.
• Documentary confirmed malignant neoplasms.
• Documentary confirmed lung diseases associated with respiratory failure.
• Treatment of Human Immunodeficiency Virus-1 with immunotherapeutic vaccines within 90 days prior to screening.
• Necessity in assignment of antimycobacterial therapy.
• Pregnancy, lactation period.
• Documentary confirmed retinopathy (for example, cytomegalovirus retinitis, macular degeneration).
• Severe concurrent diseases (for example, severe arterial hypertension, sever coronary heart disease, heart failure, decompensated diabetes mellitus and other) which are contraindications for antiviral therapy according to the investigator opinion.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Algeron; Algeron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg)	Drug: Algeron; 1.5 µg/kg of body weight subcutaneously, once a week; Other Names: Cepeginterferon alfa-2b
Active Comparator: PegIntron; PegIntron at a dose of 1.5 µg/kg of body weight subcutaneously, once a week, and Rebetol, orally, at a daily dose of 800 mg (for body weight <65 kg), 1,000 mg (for body weight 65 - 85 kg), 1,200 mg (for body weight 86 - 105 kg) or 1,400 mg (for body weight > 105 kg).	Drug: PegIntron; 1.5 µg/kg of body weight subcutaneously, once a week; Other Names: peginterferon alfa-2b

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Early Virological Response	Proportion of randomized patients achieving early virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment	12 weeks
Early Virological Response in Patients With Different Hepatitis C Virus Genotypes	Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving early virologic response - negative polymerase chain reaction result for HCV ribonucleic acid (< 15 IU/ml) or ≥ 2log10 decrease of viral load after 12 weeks of study treatment	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rapid Virological Response	Proportion of randomized patients achieving rapid virologic response - negative polymerase chain reaction result for Hepatitis C Virus ribonucleic acid (< 15 IU/ml) after 4 weeks of treatment	4 weeks
Rapid Virological Response in Patients With Different Hepatitis C Virus Genotypes	Proportion of randomized patients with different Hepatitis C Virus (HCV) genotypes achieving rapid virological response - negative polymerase chain reaction result for HCV ribonucleic acid (< 15 IU/ml) after 4 weeks of treatment	4 weeks
Viral Breakthrough	Proportion of patients in each groups with level of Hepatitis C Virus ribonucleic acid > 15 IU/ml after Hepatitis C Virus ribonucleic acid was not present or Hepatitis C Virus ribonucleic acid was increased by more than 1log10 from baseline at 4 or 12 weeks of treatment	screening data and at 4 or 12 weeks of treatment.
Biochemical Response	Proportion of patients in each group with alanine aminotransferase level ≤ upper normal limit after 12 weeks of therapy	12 weeks

Collaborators and Investigators

• Sponsor: Biocad
• Investigators: Principal Investigator: Gregory Moshkovich, M.D., State Institution of Nizhny Novgorod region "Regional Center for Prevention and Control of AIDS and other infectious diseases"; Principal Investigator: Firaya Nagimova, PhD, State Public Healthcare Institution National Center for the Prevention and Control of AIDS and other infectious diseases of the Ministry of Health of the Republic of Tatarstan; Principal Investigator: Oleg Kozyrev, PhD, State Healthcare Institution "Volgograd Regional Center for the Prevention and Control of AIDS and infectious diseases"; Principal Investigator: Andrey Shuldyakov, M.D., PhD, State Budgetary Higher Vocational Education Institution V.I. Razumovsky Saratov State University of medicine; Principal Investigator: Vadim Rassokhin, PhD, State Healthcare Institution Center for the Prevention and Control of AIDS and infectious diseases of the city, St.Petersburg CityHealth Department; Principal Investigator: Lidia Sklar, M.D., PhD, State Budgetary Higher Vocational Education Institution Pacific State Medical University, Ministry of Health of the Russian Federation

Study record dates

Study Major Dates

• Study Start (Actual): June 6, 2013
• Primary Completion (Actual): August 26, 2015
• Study Completion (Actual): August 26, 2015

Study Registration Dates

• First Submitted: April 1, 2014
• First Submitted That Met QC Criteria: April 1, 2014
• First Posted (Estimate): April 3, 2014

Study Record Updates

• Last Update Posted (Actual): August 9, 2018
• Last Update Submitted That Met QC Criteria: July 13, 2018
• Last Verified: July 1, 2018

More Information

Terms related to this study

• Keywords: Treatment; Hepatitis C; Peginterferon; Cepeginterferon alfa
• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Sexually Transmitted Diseases, Viral; Sexually Transmitted Diseases; Lentivirus Infections; Retroviridae Infections; Immune System Diseases; Liver Diseases; Flaviviridae Infections; Hepatitis, Viral, Human; Enterovirus Infections; Picornaviridae Infections; Hepatitis, Chronic; Slow Virus Diseases; HIV Infections; Hepatitis; Hepatitis A; Hepatitis C; Acquired Immunodeficiency Syndrome; Immunologic Deficiency Syndromes; Hepatitis C, Chronic; Coinfection; Anti-Infective Agents; Antiviral Agents; Peginterferon alfa-2b
• Other Study ID Numbers: BCD-016-4

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No